-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: AMP v. Myriad Genetics
USPTO Issues New Myriad Guidance
On Tuesday, December 16 the United States Patent and Trademark Office issued a revised guidance on subject matter eligibility under § 101 in light of recent Supreme Court Decisions in Alice v. CLS Bank, Mayo, and Myriad. These new guidelines are a response to extensive feedback provided from industry leaders and inventors over the last several months. (BIO provided both initial and supplemental comments on the Office’s March Subject Matter Eligibility Guidance). Public comments on the Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, biotechnology patent, Mayo, Mayo v. Prometheus, Myriad, patent, patent claim, patent law, patent litigation, Patent Reform, product of nature, subject matter eligibility, United States Patent and Trademark Office, USPTO
Tags: Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, biotechnology patent, Mayo, Mayo v. Prometheus, Myriad, patent, patent claim, patent law, patent litigation, Patent Reform, product of nature, subject matter eligibility, United States Patent and Trademark Office, USPTO
BIO Submits Joint Supplemental Comments on the USPTO March Guidance
Last week BIO, alongside a number of member companies and private individuals, submitted supplemental comments to the U.S. Patent and Trademark Office concerning their March 2014 Guidance on patent subject matter eligibility. In July, BIO and international bio-industry associations had submitted comments to the USPTO expressing concern about the Guidance, and its impact on the patent eligibility of biotechnology inventions. Since July, USPTO staff has indicated a final revision to the Guidance would be released Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: 101 analysis, Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, Benson, Bilski, biotech industry, Biotech Patent, biotechnology, Diamond v. Chakrabarty, Diehr, Flook, Funk Bros, Industry Analysis, ineligible claim, Intellectual Property, J.E.M. Ag-Supply, March Guidance, Michelle Lee, Myriad, patent, subject matter eligibility, U.S. Patent and Trademark Office, USPTO, USPTO Guidance
Tags: 101 analysis, Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, Benson, Bilski, biotech industry, Biotech Patent, biotechnology, Diamond v. Chakrabarty, Diehr, Flook, Funk Bros, Industry Analysis, ineligible claim, Intellectual Property, J.E.M. Ag-Supply, March Guidance, Michelle Lee, Myriad, patent, subject matter eligibility, U.S. Patent and Trademark Office, USPTO, USPTO Guidance
Detailed Report Examines the Crucial Role of Patents in Genetic Testing
In The Critical Role of Patents in the Development, Commercialization, and Utilization of Innovative Genetic Diagnostic Tests, Professor Holman argues that advocates for weakening patent protection have fundamental misconceptions on the role of patents in genetic testing. Opponents assume that patents negatively impact patient access to genetic diagnostic testing. They believe that patents inhibit research that could lead to new or improved versions of genetic tests, and that patent holders charge higher prices as exclusive Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: AMP v. Myriad, AMP v. Myriad Genetics, BIOTECH, Biotech Patent, Biotech Patenting, Diagnostic tests, federal patents, Gene Patents, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patents, SCOTUS, United States Supreme Court
Tags: AMP v. Myriad, AMP v. Myriad Genetics, BIOTECH, Biotech Patent, Biotech Patenting, Diagnostic tests, federal patents, Gene Patents, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patents, SCOTUS, United States Supreme Court
PTO Patent Examinations in the wake of Mayo and Myriad
Biotech patent applicants are finding themselves in uncharted waters. After the Supreme Court’s decisions in Mayo Collaborative Svs. v. Prometheus Labs and Ass’n for Molecular Pathology v. Myriad Genetics, companies have been trying to understand how these decisions will impact the industry. A recent study supported by BIO, in collaboration with Bloomberg BNA and the law firm of Robins, Kaplan, Miller & Ciresi analyzed how Mayo and Myriad have changed patent eligibility for biotechnology. Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: AMP v. Myriad Genetics, BIO, BIOTECH, biotech industry, biotechnology, Biotechnology Industry, Bloomberg BNA, business development, Intellectual Property, IP Protection, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patent, patent filings, Patents in the Supreme Court, public policy, Stopped at the Threshold, Supreme Court decision, USPTO
Tags: AMP v. Myriad Genetics, BIO, BIOTECH, biotech industry, biotechnology, Biotechnology Industry, Bloomberg BNA, business development, Intellectual Property, IP Protection, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, Myriad Case, patent, patent filings, Patents in the Supreme Court, public policy, Stopped at the Threshold, Supreme Court decision, USPTO
Debunking the Myth: Your Genes are Patented
MYTH: YOUR GENES ARE PATENTED. FACTS: IT IS NOT POSSIBLE TO PATENT YOUR GENES The term “gene patent” is a misnomer, because genes as they exist in the body cannot be patented. Because a naturally-occurring gene – even a newly-discovered one – cannot be patented, patents don’t provide ownership rights over our genes, and nobody can infringe a patent by having a certain gene, or by passing it on to their children. If genes aren’t Read More >
